Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?
作者信息
Nasrallah Gheyath K
机构信息
Member of QU Health, Department of Biomedical Science, College of Health Sciences, Qatar University, P.O. Box 2713, Doha, Qatar; Biomedical Research Center, Qatar University, Doha, Qatar.
出版信息
EBioMedicine. 2022 Feb;76:103831. doi: 10.1016/j.ebiom.2022.103831. Epub 2022 Jan 23.
Abstract
摘要
相似文献
1
Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?
EBioMedicine. 2022 Feb;76:103831. doi: 10.1016/j.ebiom.2022.103831. Epub 2022 Jan 23.
2
The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients.
Biochem Biophys Res Commun. 2021 Mar 5;543:45-49. doi: 10.1016/j.bbrc.2021.01.073. Epub 2021 Jan 22.
3
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
4
Circulating CD4 T Cells Elicited by Endemic Coronaviruses Display Vast Disparities in Abundance and Functional Potential Linked to Antigen Specificity and Age.
J Infect Dis. 2021 May 20;223(9):1555-1563. doi: 10.1093/infdis/jiab076.
5
Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.
J Clin Invest. 2021 Nov 1;131(21). doi: 10.1172/JCI150613.
6
How kids' immune systems can evade COVID.
Nature. 2020 Dec;588(7838):382. doi: 10.1038/d41586-020-03496-7.
7
Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
J Gen Virol. 2021 Nov;102(11). doi: 10.1099/jgv.0.001692.
8
Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
J Virol. 2021 Feb 24;95(6). doi: 10.1128/JVI.02002-20.
9
Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France.
EBioMedicine. 2021 Sep;71:103580. doi: 10.1016/j.ebiom.2021.103580. Epub 2021 Sep 12.
10
Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
mBio. 2021 Jun 29;12(3):e0122921. doi: 10.1128/mBio.01229-21.
引用本文的文献
1
Persistent immune and clotting dysfunction detected in saliva and blood plasma after COVID-19.
Heliyon. 2023 Jul 4;9(7):e17958. doi: 10.1016/j.heliyon.2023.e17958. eCollection 2023 Jul.
2
Coronavirus spike protein-specific antibodies indicate frequent infections and reinfections in infancy and among BNT162b2-vaccinated healthcare workers.
Sci Rep. 2023 May 24;13(1):8416. doi: 10.1038/s41598-023-35471-3.
3
Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.
mBio. 2023 Feb 28;14(1):e0328722. doi: 10.1128/mbio.03287-22. Epub 2023 Jan 10.
4
Improving Nasal Protection for Preventing SARS-CoV-2 Infection.
Biomedicines. 2022 Nov 17;10(11):2966. doi: 10.3390/biomedicines10112966.
Zotero 插件